https://innodemneurosciences.com/blogs/tech-promo/eye-movement-biomarkers-embs 2024-02-14T10:07:55-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1136684040.jpg?v=1707923275 Eye Movement Biomarkers (EMBs) Changes in eye movements can be observed as we age or when there is an erosion of neural functioning due to disease or injury, suggesting a direct correlation between brain health and eye movements. https://innodemneurosciences.com/blogs/tech-promo/gaze-mapping-biomarkers-gmbs 2024-02-14T10:07:34-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/Innodem-gaze-mapping.jpg?v=1707923254 Gaze Mapping Biomarkers (GMBs) Gaze Mapping Biomarkers (GMBs) are distinct from EMBs as they quantitatively measure aspects of cognition by analyzing gaze patterns that are produced while individuals perform short visual tasks. https://innodemneurosciences.com/blogs/tech-promo/innodem-artificial-intelligence 2024-02-14T10:07:03-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1415099907.jpg?v=1707923223 Artificial Intelligence Innodem, a company led by a team of neurologists, neuroscientists, AI experts, data scientists, and software engineers, has patented its newly developed technology in North America, Europe, and Asia. https://innodemneurosciences.com/blogs/clinical-trials/cancer-related-cognitive-impairment 2024-02-14T10:06:15-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1496430326.jpg?v=1707923175 Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI) Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI) https://innodemneurosciences.com/blogs/clinical-trials/investigating-eye-movement-biomarkers-in-multiple-sclerosis 2024-02-14T10:05:06-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1490284717.jpg?v=1707923106 Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis https://innodemneurosciences.com/blogs/clinical-trials/multiple-sclerosis-rrms-spms 2024-02-14T10:05:24-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1320042590.jpg?v=1707923124 Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis https://innodemneurosciences.com/blogs/clinical-trials/development-and-validation-of-a-novel-functional-eye-tracking-software-application-for-alzheimers-disease 2024-02-14T10:05:56-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1444487641.jpg?v=1707923156 Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease https://innodemneurosciences.com/blogs/clinical-trials/implementation-of-a-novel-functional-eye-tracking-biomarker-for-multiple-sclerosis 2024-02-14T10:05:41-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1555819215.jpg?v=1707923141 Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis https://innodemneurosciences.com/blogs/publications/oculomotor-analysis-to-assess-brain-health-preliminary-findings-from-a-longitudinal-study-of-multiple-sclerosis-using-novel-tablet-based-eye-tracking-software 2024-02-14T10:11:30-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-537954739.jpg?v=1707923490 Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software https://innodemneurosciences.com/blogs/publications/a-novel-tablet-based-software-for-the-acquisition-and-analysis-of-gaze-and-eye-movement-parameters-a-preliminary-validation-study-in-parkinson-s-disease 2024-01-14T23:00:49-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1407303692.jpg?v=1705291249 A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease https://innodemneurosciences.com/blogs/press-releases/a-leading-neurologist-joins-innodem-neurosciences 2024-02-14T10:10:55-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/2675-small.jpg?v=1707923455 A Leading Neurologist Joins Innodem Neurosciences Innodem Neurosciences is proud to announce the appointment of a leading authority on neurodegenerative and mental diseases, Dr. Paul Giacomini, M.D., FRCPC, as the company’s Chief Medical Officer. https://innodemneurosciences.com/blogs/press-releases/innodem-neurosciences-signs-a-strategic-commercial-framework-agreement-with-novartis-pharmaceuticals-canada-inc 2024-02-14T10:11:12-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/2454-small.png?v=1707923472 Innodem Neurosciences signs a strategic commercial framework agreement with Novartis Pharmaceuticals Canada Inc. Innodem Neurosciences signs a strategic commercial framework agreement with Novartis Pharmaceuticals Canada Inc. https://innodemneurosciences.com/blogs/press-releases/oculomotor-analysis-to-assess-brain-health-preliminary-findings-from-a-longitudinal-study-of-multiple-sclerosis-using-novel-tablet-based-eye-tracking-software 2024-02-14T10:09:15-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1501969988.jpg?v=1707923355 Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software https://innodemneurosciences.com/blogs/press-releases/a-novel-tablet-based-software-for-the-acquisition-and-analysis-of-gaze-and-eye-movement-parameters-a-preliminary-validation-study-in-parkinson-s-disease 2024-02-14T10:09:38-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1439950058.jpg?v=1707923378 A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease https://innodemneurosciences.com/blogs/press-releases/etna%E2%84%A2-device-from-leading-digital-health-ai-company-innodem-neurosciences-receives-fda-breakthrough-designation-for-multiple-sclerosis 2024-02-14T10:04:39-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1285787932.jpg?v=1707923079 ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis https://innodemneurosciences.com/blogs/press-releases/innodem-neurosciences-signs-a-strategic-partnership-with-novartis-pharmaceuticals-canada-inc 2024-02-14T10:08:18-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/X4A8842.jpg?v=1707923298 Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc. Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS). https://innodemneurosciences.com/blogs/press-releases/innodem-neurosciences-receives-6-million-us-dollars-of-financing-from-morningside-group 2024-02-14T10:08:51-05:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/2782-small.png?v=1707923331 Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group https://innodemneurosciences.com/blogs/press-releases/innodem-neuroscience-technology-featured-in-nature-the-leading-international-weekly-journal-of-science 2024-04-24T12:17:05-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1079961158.jpg?v=1713974098 Innodem Neurosciences technology featured in Nature https://innodemneurosciences.com/blogs/publications/eye-movement-function-captured-via-an-electronic-tablet-informs-on-cognition-and-disease-severity-in-parkinson-s-disease 2024-04-24T11:53:34-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1263103496.jpg?v=1713974014 Eye movement function captured via an electronic tablet informs on cognition and disease severity in Parkinson’s disease https://innodemneurosciences.com/blogs/press-releases/dr-paul-giacomini-radio-interview-on-cbc-breakaway-with-alison-brunette 2024-04-24T12:13:50-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/2743-cropped-edited.jpg?v=1713975083 Dr. Paul Giacomini Radio interview on CBC - Breakaway with Alison Brunette https://innodemneurosciences.com/blogs/press-releases/innodem-neurosciences-etna%E2%84%A2-ms-obtains-health-canadas-approval 2024-04-24T12:27:42-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/2442.jpg?v=1713976027 Innodem Neurosciences' ETNA™-MS obtains Health Canada's Approval https://innodemneurosciences.com/blogs/press-releases/canadian-biomarker-research-how-could-it-improve-the-standard-of-care-in-ms 2024-04-24T12:31:19-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1477483014.jpg?v=1713976279 Canadian biomarker research: How could it improve the standard of care in MS? https://innodemneurosciences.com/blogs/press-releases/partnership-effort-leverages-ai-to-help-detect-disease-progression-in-multiple-sclerosis 2024-04-24T12:37:13-04:00 weekly https://cdn.shopify.com/s/files/1/0850/1290/6264/articles/iStock-1399246824.jpg?v=1713976587 Partnership effort leverages AI to help detect disease progression in multiple sclerosis